Medtronic Enters New Outcomes-Based Insulin Pump Deal With Aetna
The device-maker will be on the hook to provide rebates to the health insurer if its self-adjusting insulin pumps don't maintain patients in appropriate glucose ranges, under a newly inked agreement. Medtronic already has a similar arrangement with UnitedHealthcare.
You may also be interested in...
Medtronic and UnitedHealthcare have evidence that their year-old partnership is improving health outcomes in diabetes patients that require intensive insulin delivery. An analysis of more than 6,000 UnitedHealthcare members with diabetes who used Medtronic's MiniMed 630G and previous generation insulin pumps between July 2016 and July 2017 showed 27% fewer preventable hospital admissions compared to plan-participants who were using multiple daily injections of insulin.
US FDA recently approved the first 90-day CGM system and expanded the labeling for a closed-loop system to treat diabetes.
Medtronic Diabetes exec Suzanne Winter talks with Medtech Insight about her business' approach to value-based health care, including recently inked agreements with insurers such as Aetna and United Healthcare.